Meningococcal Infections: all 243 studies

Page 1 of 3. Open to participants first (8), then studies with results posted, then the rest; newest registration first within each.

• Single-center, Open-label Study: Immunogenicity and Safety Observation After Vaccination With ACYW135 Meningococcal Polysaccharide Vaccine in Junior High School Students Aged 13-15 YearsNot yet recruitingNCT07885371Phase 4
• A Study to Learn About the Safety of PENBRAYA During PregnancyRecruitingNCT07768163
• Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in ChinaRecruitingNCT07710872Phase 3
• Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years OldRecruitingNCT07204457Phase 2/3
• Meningococcal B Vaccine in Patients with AspleniaRecruitingNCT06025487Phase 2
• Epidemiological, Clinical and Biological Caracteristics of Patients Presenting With Invasive Meningococcal DiseaseRecruitingNCT05981599
• Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIVRecruitingNCT04875819Phase 4
• Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)RecruitingNCT04843111
• Study on a MenACYW Conjugate Vaccine Administered as a Single Dose in Participants Aged 12 Months and Older in VietnamCompletedNCT06228586Phase 3Results posted
• A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy InfantsCompletedNCT05082285Phase 2Results posted
• A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and AdultsCompletedNCT04886154Phase 1/2Results posted
• Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY VaccineCompletedNCT04707391Phase 3Results posted
• Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young AdultsCompletedNCT04502693Phase 3Results posted
• Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of AgeCompletedNCT04318548Phase 3Results posted
• Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49CompletedNCT04142242Phase 3Results posted
• Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and LebanonCompletedNCT03869866Phase 3Results posted
• Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and ToddlersCompletedNCT03691610Phase 3Results posted
• Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and ToddlersCompletedNCT03673462Phase 3Results posted
• A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of AgeCompletedNCT03652610Phase 2Results posted
• Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United KingdomCompletedNCT03632720Phase 3Results posted
• Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and MexicoCompletedNCT03630705Phase 3Results posted
• Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy InfantsCompletedNCT03621670Phase 3Results posted
• Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in EuropeCompletedNCT03547271Phase 3Results posted
• Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the USCompletedNCT03537508Phase 3Results posted
• A Sourcing Study to Collect Human Blood Samples From Healthy AdultsCompletedNCT03493919Phase 4Results posted
• Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in ChildrenCompletedNCT03476135Phase 3Results posted
• A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of AgeCompletedNCT03433482Phase 2Results posted
• Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in ToddlersCompletedNCT03205371Phase 3Results posted
• Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy ToddlersCompletedNCT03205358Phase 2Results posted
• Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 YearsCompletedNCT03077438Phase 3Results posted
• Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY VaccinationCompletedNCT02986854Phase 3Results posted
• Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in ToddlersCompletedNCT02955797Phase 3Results posted
• Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in AdolescentsCompletedNCT02946385Phase 2Results posted
• Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and OlderCompletedNCT02842866Phase 3Results posted
• Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate VaccineCompletedNCT02842853Phase 3Results posted
• Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate VaccineCompletedNCT02752906Phase 3Results posted
• Safety of 4CMenB Exposure During PregnancyCompletedNCT02640677Results posted
• Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in VietnamCompletedNCT02640404Phase 2Results posted
• Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate VaccineCompletedNCT02639351Phase 1Results posted
• Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years EarlierCompletedNCT02633787Phase 4Results posted
• Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult SubjectsCompletedNCT02591290Phase 4Results posted
• Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)CompletedNCT02569632Phase 4Results posted
• A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 YearsCompletedNCT02531698Phase 2Results posted
• A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)CompletedNCT02451514Phase 2Results posted
• Combined Study - Phase 3b MenB Long Term Persistence in AdolescentsCompletedNCT02446743Phase 3Results posted
• Evaluation of Antibody Persistence Following 4 MenACWY VaccinationsCompletedNCT02446691Phase 4Results posted
• Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant StudyCompletedNCT02287688Results posted
• Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy AdolescentsCompletedNCT02285777Phase 2Results posted
• Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy RegistryCompletedNCT02223637Results posted
• Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in AdolescentsCompletedNCT02212457Phase 2Results posted
• Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy AdolescentsCompletedNCT02199691Phase 2Results posted
• Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.CompletedNCT02173704Phase 3Results posted
• Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.CompletedNCT02141516Phase 3Results posted
• Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy AdolescentsCompletedNCT02140762Phase 2Results posted
• Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy InfantsCompletedNCT02106390Phase 3Results posted
• Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy ToddlersCompletedNCT01994629Phase 2Results posted
• Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)CompletedNCT01992536Phase 2Results posted
• Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.CompletedNCT01973218Phase 3Results posted
• The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary VaccinationCompletedNCT01962207Phase 3Results posted
• Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™VaccineCompletedNCT01939158Phase 3Results posted
• Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary VaccinationCompletedNCT01934140Phase 3Results posted
• A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.CompletedNCT01911221Phase 3Results posted
• Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy ChildrenCompletedNCT01900899Phase 3Results posted
• Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate VaccineCompletedNCT01897402Phase 2Results posted
• Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian FederationCompletedNCT01890759Phase 3Results posted
• Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster DoseCompletedNCT01823536Phase 4Results posted
• Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary VaccinationCompletedNCT01777308Phase 3Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of AgeCompletedNCT01767376Phase 3Results posted
• Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South KoreaCompletedNCT01766206Phase 4Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young AdultsCompletedNCT01755689Phase 3Results posted
• Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and OlderCompletedNCT01732627Phase 2Results posted
• Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in RussiaCompletedNCT01725217Phase 3Results posted
• Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1CompletedNCT01717638Phase 3Results posted
• Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to ChildrenCompletedNCT01689155Results posted
• Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.CompletedNCT01682876Phase 3Results posted
• Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of AgeCompletedNCT01659996Phase 4Results posted
• Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South KoreaCompletedNCT01642589Phase 3Results posted
• Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy SubjectsCompletedNCT01641042Phase 3Results posted
• Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster DoseCompletedNCT01543087Phase 3Results posted
• Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese SubjectsCompletedNCT01519713Phase 3Results posted
• A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk AdultsCompletedNCT01478347Phase 3Results posted
• A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in AdultsCompletedNCT01466387Phase 3Results posted
• Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate VaccineCompletedNCT01453348Phase 3Results posted
• Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra VaccineCompletedNCT01442675Phase 2Results posted
• Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy ToddlersCompletedNCT01434680Phase 2Results posted
• Study of Sanofi Pasteur and Lanzhou Institute's Meningococcal (Group A and C) Polysaccharide Vaccine in ChildrenCompletedNCT01430611Phase 4Results posted
• Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 YearsCompletedNCT01423084Phase 3Results posted
• Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study VaccinesCompletedNCT01367158Phase 2Results posted
• Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine ImmunizationsCompletedNCT01359449Phase 3Results posted
• Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate VaccineCompletedNCT01345721Phase 3Results posted
• Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and ToddlersCompletedNCT01340898Phase 3Results posted
• A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 YearsCompletedNCT01339923Phase 3Results posted
• A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in KoreaCompletedNCT01274897Phase 3Results posted
• Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young AdultsCompletedNCT01272180Phase 2Results posted
• Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the PhilippinesCompletedNCT01270503Phase 4Results posted
• Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy ChildrenCompletedNCT01266993Phase 3Results posted
• Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial VaccinationCompletedNCT01239043Phase 2Results posted
• Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 YearsCompletedNCT01235975Phase 3Results posted
• Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of LifeCompletedNCT01214837Phase 3Results posted
• Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/AdultsCompletedNCT01165242Phase 2Results posted

← Meningococcal Infections overview